CVI, Heights report 3.8% Pasithea stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Pasithea Therapeutics Corp. received an updated ownership report from institutional investors CVI Investments, Inc. and Heights Capital Management, Inc. The Reporting Persons state beneficial ownership of 899,994 shares of Pasithea common stock, representing 3.8% of the outstanding shares as of the referenced date.
The position consists of shares issuable upon exercise of warrants, which are subject to a 9.99% beneficial ownership limitation that caps how many shares can be acquired at any time. Pasithea’s definitive proxy indicates 23,091,062 shares of common stock were outstanding as of December 22, 2025, providing context for the reported 3.8% stake.
CVI Investments, Inc. is organized in the Cayman Islands and Heights Capital Management, Inc. in Delaware. Heights acts as investment manager to CVI and may exercise voting and dispositive power over the reported shares, while both parties disclaim beneficial ownership beyond their economic interest.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Pasithea Therapeutics Corp. (KTTA) is reported in this Schedule 13G/A amendment?
Who are the reporting persons in the Pasithea Therapeutics Corp. (KTTA) Schedule 13G/A?
How is the 3.8% ownership of KTTA common stock calculated in this filing?
What kind of securities do CVI and Heights hold in Pasithea Therapeutics Corp. (KTTA)?
What does the 9.99% beneficial ownership limitation mean for KTTA warrants?
What certification do the reporting persons make about their KTTA holdings?
AI-generated analysis. How Rhea-AI works. Not financial advice.